Company intelligence / Profile preview

Taysha Gene Therapies

Dallas, Texas, United States

Ownership: Private
Employees: ~73
Development stage: Other

Overview

Taysha Gene Therapies is a clinical-stage company developing AAV-based gene therapies for monogenic CNS diseases, currently led by TSHA‑102 for Rett syndrome in Phase 1/2 trials; the company has reported encouraging early Rett data and received FDA alignment and Breakthrough Therapy-type regulatory momentum, while earlier broad pipeline programs have been narrowed to focus on its most promising CNS gene therapy candidates.

Therapeutic areas: NeurologyRare Diseases
Modalities: Gene therapyBiologic
Industry: Biotech

Partnerships

Research, collaboration and license agreement with The University of Texas Southwestern Medical Center for AAV-based gene therapy programs for monogenic CNS diseases.

Beyond the preview

Go deeper on Taysha Gene Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taysha Gene Therapies.

Explore the full profile